San Diego Biomedical Research Institute

San Diego Biomedical Research Institute, a non-profit research organization based in San Diego, California, receives federal research funding as a prime grant recipient across multiple National Institutes of Health (NIH) institutes, with recent awards totaling $114.3 million across 42 grants and sub-awards concentrated in immunology, neurology, infectious disease, and cancer research.

The institute operates as a prime recipient on 88% of its federal awards, with five sub-award positions under Carnegie-Mellon University and the University of California, San Diego on genomics and mechanistic research initiatives. The NIH's National Institute of Allergy and Infectious Diseases (NIAID) leads the customer portfolio with eight awards, followed closely by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS), each with seven awards; the National Cancer Institute and National Institute on Aging each account for four awards. These five customer agencies cover 71% of recent awards by count. Activity has grown from four awards annually in 2022 and 2023 to seven in 2024, with three awards in 2025 and four year-to-date in 2026.

Representative prime recipient work includes a $992,920 five-year NIAID project grant (CFDA 93.855) awarded September 1, 2026, on nanoscale imaging of HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity therapeutics, integrating machine learning and in silico protein modeling; a $809,479 NIAID project grant (CFDA 93.855) awarded June 4, 2026, designing engineered native HIV envelope glycoprotein trimers to induce broadly neutralizing antibodies targeting the CD4-binding site; and a $541,750 National Institute of Neurological Disorders and Stroke project grant (CFDA 93.853) awarded May 15, 2026, discovering noncanonical autophagy modulators for Alzheimer's disease and related dementias using complementary intracellular functional screening platforms. Additional recent funding includes a $1.436 million National Heart, Lung, and Blood Institute project grant (CFDA 93.837) awarded September 20, 2025, assessing CD4+ cytotoxic T lymphocytes in severe asthma response to Type 2 biologic therapies, and multiple NIAID awards on HIV antibody glycosylation, calorie restriction and lupus autoimmunity, and allergen-responsive T cell subsets in allergy and asthma.

NIDA funding supports mechanistic research on methamphetamine, HIV integration and latency in the brain (R61/R33 phase funding, September 30, 2023, through August 31, 2028) and cannabinoid effects on blood-brain barrier integrity in HIV-infected brain (August 15, 2024, through May 31, 2029). Sub-recipient roles include genomics data production and blood-brain barrier mechanistic studies executed through University of California, San Diego and Carnegie-Mellon University prime recipients. Performance occurs in San Diego, California. Ten awards reach ultimate completion within the next twenty-four months, representing near-term recompete exposure across the NIAID, NINDS, and NIDA portfolios.